Stock RCUS ARCUS BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Arcus Biosciences, Inc.

Equities

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-25 pm EDT 		5-day change 1st Jan Change
14.73 USD -4.54% Intraday chart for Arcus Biosciences, Inc. -0.74% -22.88%
Mar. 12 Transcript : Arcus Biosciences, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM
Feb. 29 Arcus Biosciences Insider Sold Shares Worth $1,177,967, According to a Recent SEC Filing MT

Business Summary

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Number of employees: 577

Sales per Business

USD in Million2022Weight2023Weight Delta
Immunotherapies
100.0 %
112 100.0 % 117 100.0 % +4.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
112 100.0 % 117 100.0 % +4.46%

Managers

Managers TitleAgeSince
Juan Jaen FOU
 Founder 66 14-12-31
Terry Rosen CEO
 Chief Executive Officer 64 14-12-31
Robert Goeltz DFI
 Director of Finance/CFO 51 20-07-31
Dimitry Nuyten CTO
 Chief Tech/Sci/R&D Officer - 22-07-31
Steve Young CTO
 Chief Tech/Sci/R&D Officer 55 16-02-29
Jennifer Jarrett COO
 Chief Operating Officer 53 17-02-28
Jonathan Yingling CTO
 Chief Tech/Sci/R&D Officer 55 19-12-31
Eric Matthews PRN
 Corporate Officer/Principal - 19-06-23
Alexander Azoy AUD
 Comptroller/Controller/Auditor 48 20-10-01
Carolyn Tang LAW
 General Counsel 45 17-06-30

Members of the board

Members of the board TitleAgeSince
Terry Rosen CEO
 Chief Executive Officer 64 14-12-31
Kathryn Falberg BRD
 Director/Board Member 63 17-09-17
Yasunori Kaneko BRD
 Director/Board Member 69 15-04-30
Juan Jaen FOU
 Founder 66 14-12-31
Merdad Parsey BRD
 Director/Board Member 61 20-07-12
Antoni Ribas BRD
 Director/Board Member 57 19-10-27
David Lacey BRD
 Director/Board Member 71 20-05-20
Nicole Lambert BRD
 Director/Board Member 50 21-08-02
Jennifer Jarrett COO
 Chief Operating Officer 53 17-02-28
Johanna Mercier BRD
 Director/Board Member 54 Jan. 28

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 90,952,836 53,540,725 ( 58.87 %) 0 58.87 %

Shareholders

NameEquities%Valuation
GILEAD SCIENCES, INC.
34.70 %
31,532,781 34.70 % 595 M $
BlackRock Advisors LLC
10.46 %
9,504,562 10.46 % 179 M $
Fidelity Management & Research Co. LLC
5.204 %
4,728,782 5.204 % 89 M $
Vanguard Fiduciary Trust Co.
5.151 %
4,680,716 5.151 % 88 M $
STATE STREET CORPORATION
4.666 %
4,239,577 4.666 % 80 M $
Terry Rosen
4.366 %
3,966,974 4.366 % 75 M $
Octagon Capital Advisors LP
2.056 %
1,868,000 2.056 % 35 M $
Ameriprise Trust Co.
1.799 %
1,634,805 1.799 % 31 M $
Invus Financial Advisors LLC
1.774 %
1,612,077 1.774 % 30 M $
Boxer Capital LLC
1.763 %
1,602,200 1.763 % 30 M $

Company contact information

Arcus Biosciences, Inc.

3928 Point Eden Way

94545, Hayward

+

http://www.arcusbio.com
address Arcus Biosciences, Inc.(RCUS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for Arcus Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.73 USD
Average target price
39.67 USD
Spread / Average Target
+169.29%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARCUS BIOSCIENCES, INC. Stock Arcus Biosciences, Inc.
-22.88% 1.34B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+47.36% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RCUS Stock
  4. Company Arcus Biosciences, Inc.